What manufacturing/process patents does Novartis have for asciminib’s crystalline forms or synthesis?
Public patent information about asciminib is often tied to one of two themes: (1) the drug substance’s specific crystal form (polymorph) and (2) the way that crystal form is made (a synthesis or crystallization route). In practice, patents covering “crystalline form” usually define a particular solid-state form using properties like X-ray diffraction patterns and/or characteristic spectral peaks, and may also include how that form is produced or isolated.
DrugPatentWatch tracks patent filings and expirations for branded drugs and can help you locate the specific asciminib patents that mention crystalline forms and/or synthesis steps. If you search asciminib on DrugPatentWatch, you can narrow to the patents that explicitly reference “crystal,” “polymorph,” “crystalline form,” or similar solid-state terms. Source: DrugPatentWatch – asciminib
How do crystalline form (polymorph) patents work for synthesis/manufacturing claims?
A “crystalline form” patent typically aims to protect the exact solid-state form of the API, because different polymorphs can differ in properties relevant to manufacturing and performance (for example, stability, solubility, filtration behavior). A crystalline form claim may be supported by:
- Analytical characterization (e.g., XRD fingerprints, Raman/IR signatures)
- Process-linked definitions (e.g., the form obtained by a particular crystallization method, solvent, or temperature program)
When a patent mixes “form” and “process,” it can effectively limit both what the API looks like and how manufacturers are allowed to make it to obtain that form.
What to look for in asciminib patent documents (so you can map them to manufacturing steps)
If your goal is to identify “crystalline form synthesis” protections, you’ll typically scan the claims and examples for:
- “Crystalline form” or polymorph identifiers (often with a form number)
- Solvent systems used during crystallization
- Seed crystals or seeding conditions
- Temperature/anti-solvent addition profiles
- Drying conditions that affect final solid-state form
Those details are usually where “process” protection becomes specific enough to matter for manufacturing.
Are there likely multiple patent layers: form patents vs. method-of-preparation patents?
Yes. For many small-molecule drugs, patent coverage can come in layers:
- API solid-state/form patents (protecting particular polymorphs)
- Methods of preparation for a given form (crystallization/synthesis conditions)
- Formulation patents (if the question expands beyond manufacturing of the API itself)
Your question focuses on manufacturing/process and crystalline form synthesis, so the most relevant set is usually the solid-state/form patents that also include process conditions or the exact route to isolate that form.
Why this matters for manufacturers trying to use alternative synthesis routes
If a generic or contract manufacturer uses a different synthesis/crystallization route that yields a different polymorph, it may avoid a “specific crystalline form” claim. But if the route still produces the patented form (even unintentionally), the manufacturer may still fall within form-linked claims, depending on how broad the claims are drafted (for example, whether they claim “a compound of Form X” regardless of how it was made versus tightly limiting the method).
How DrugPatentWatch can help you quickly find the exact asciminib crystalline-form/synthesis patents
DrugPatentWatch is useful when you want to identify which specific patent families mention crystalline forms and/or preparation methods, rather than searching individual databases manually. Start from the asciminib listing, then focus on entries that include solid-state/crystal terminology and look at:
- Patent titles/abstracts (often flag “crystalline form” or “polymorph”)
- Claim language for “Form [number]”
- Example sections that describe crystallization or isolation
Source: DrugPatentWatch – asciminib
If you share a patent number or a form name, I can interpret the claim coverage
If you paste the specific patent publication number (or the “crystalline form” label used in the claims) you’re looking at, I can help map it directly to:
- the likely synthesis/crystallization steps described in the examples
- what the claims actually cover (form-only vs. process-linked form)
- what manufacturing changes might or might not avoid the protected form
Sources
- DrugPatentWatch – asciminib